Paradigm Biopharmaceuticals Limited (PAR.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.245 (+0.00%) as of
Key statistics
- Market cap
- 153.48M
- Forward P/E
- 1.35
- EPS (TTM)
- -0.1500
- Dividend yield
- 0.00%
- 52-week range
- 0.1350 – 0.4500
- Beta
- 0.03
- Profit margin
- 0.00%
- Analyst target
- A$1.08
- Volume
- 3.14M
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.